More Alzheimer’s drugs head for FDA review: what scientists are watching

Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen's aducanumab.

Advertisement

Nature is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

COP26: Inside the science

COP26: Inside the science

The 26th Conference of the Parties (COP26) in Glasgow in November is a pivotal moment for action on climate change.
Collection

Nature Careers

Events

Jobs